Time-to-Detection in Culture of Mycobacterium Tuberculosis

determination if time-to-detection in cultures of M. tuberculosis samples is more discriminating than acid-fast staining in transmission

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Tuberculoses Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Lung Diseases Mycobacterium Infections Respiratory Tract Diseases Respiratory Tract Infections Tuberculosis Tuberculosis, Pulmonary

Age range

2 year–94 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nice University Hospital

Nice, 06000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

have at least 1 contact case explored for tuberculosis
latent tuberculosis infection

Exclusion criteria

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

tuberculosis transmission

Time frame: 2 months

duration of Tuberculosis transmission between an infected person and a contact case
contact case tracking

Time frame: 2 months

screening time for contact cases

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Time-to-Detection in Culture of Mycobacterium Tuberculosis : Performance for Assessing Index Cases Infectivity

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Oct 5, 2022
Registry last updated: Oct 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed